In the claims:

Please cancel claims 1, 6, 7, and 12 to 28 without prejudice and replace them with the following new claims 29 to 49:

29. A method of treating a subject having a disease associated with an immune disorder comprising administering to the subject an effective amount of a peptide selected from the group consisting of SEQ ID NO 2, SEQ ID NO 3, SEQ ID NO 4, SEQ ID NO 5, mixtures thereof, and homologues, variants and derivatives of any of these, which exhibit activity the same or similar to EtxB or Ctx B, but wherein the peptide does not exhibit GM-1 binding activity.

30. A method according to claim 29 wherein peptide is SEQ ID NO 2 or a sequence exhibiting 75% homology to SEQ ID NO 2.

31. A method according to claim 29 wherein peptide is SEQ ID NO 3 or a sequence exhibiting 75% homology to SEQ ID NO 3.

32. A method according to claim 29 wherein peptide is SEQ ID NO 4 or a sequence exhibiting 75% homology to SEQ ID NO 4.

33. A method according to claim 29 wherein peptide is SEQ ID NO 5 or a sequence exhibiting 75% homology to SEQ ID NO 5.

34. A method of treating a subject having autoimmune disease, human T cell leukaemia, transplant rejection or graft-versus-host disease, allergies, or infectious disease comprising administering to the subject an effective amount of a peptide selected from the group consisting of SEQ ID NO 2, SEQ ID NO 3, SEQ ID NO 4, SEQ ID NO 5, mixtures thereof, and homologues, variants and derivatives of any of

these, which exhibit activity the same or similar to EtxB or Ctx B, but wherein the peptide does not exhibit GM-1 binding activity.

35. A method according to claim 34 wherein peptide is SEQ ID NO 2 or a sequence exhibiting 75% homology to SEQ ID NO 2.

36. A method according to claim 34 wherein peptide is SEQ ID NO 3 or a sequence exhibiting 75% homology to SEQ ID NO 3.

37. A method according to claim 34 wherein peptide is SEQ ID NO 4 or a sequence exhibiting 75% homology to SEQ ID NO 4.

38. A method according to claim 34 wherein peptide is SEQ ID NO 5 or a sequence exhibiting 75% homology to SEQ ID NO 5.

39. A method of treating a subject having diarrhoea comprising administering to the subject an effective amount of a peptide selected from the group consisting of SEQ ID NO 2, SEQ ID NO 3, SEQ ID NO 4, SEQ ID NO 5, mixtures thereof, and homologues, variants and derivatives of any of these, which exhibit activity the same or similar to EtxB or Ctx B, but wherein the peptide does not exhibit GM-1 binding activity.

40. A method according to claim 39 wherein the diarrhoea is cholera or an enterotoxin-mediated diarrhoea disease.

41. A method according to claim 39 wherein peptide is SEQ ID NO 2 or a sequence exhibiting 75% homology to SEQ ID NO 2.

42. A method according to claim 39 wherein peptide is SEQ ID NO 3 or a sequence exhibiting 75% homology to SEQ ID NO 3.

43. A method according to claim 39 wherein peptide is SEQ ID NO 4 or a sequence exhibiting 75% homology to SEQ ID NO 4.

44. A method according to claim 39 wherein peptide is SEQ ID NO 5 or a sequence exhibiting 75% homology to SEQ ID NO 5.

45. A method of treating a subject having a toxin-mediated disorder comprising administering to the subject an effective amount of a peptide selected from the group consisting of SEQ ID NO 2, SEQ ID NO 3, SEQ ID NO 4, SEQ ID NO 5, mixtures thereof, and homologues, variants and derivatives of any of these, which exhibit activity the same or similar to EtxB or Ctx B, but wherein the peptide does not exhibit GM-1 binding activity.

46. A method according to claim 45 wherein peptide is SEQ ID NO 2 or a sequence exhibiting 75% homology to SEQ ID NO 2.

47. A method according to claim 45 wherein peptide is SEQ ID NO 3 or a sequence exhibiting 75% homology to SEQ ID NO 3.

48. A method according to claim 45 wherein peptide is SEQ ID NO 4 or a sequence exhibiting 75% homology to SEQ ID NO 4.

49. A method according to claim 45 wherein peptide is SEQ ID NO 5 or a sequence exhibiting 75% homology to SEQ ID NO 5.

REMARKS

Claims 1, 6, 7, and 12 to 28 are pending in this application, which comprises a standard U.S. set of twenty claims (1, 7, 8, and 12 to 28), three of which are indepen-